View in EDS

Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses.

Saved in:
Bibliographic Details
Title: Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses.
Authors: Ajnakina, O., Trotta, A., Demjaha, A., Reis Marques, T., MacCabe, J. H., Gaughran, F., Murray, R. M., Lally, J., Shergil, S. S., Dazzan, P., David, A. S., Howes, O. D., Di Forti, M., Kolliakou, A., Mondelli, V., Pariante, C.
Source: Psychological Medicine. Nov2016, Vol. 46 Issue 15, p3231-3240. 10p.
Subjects: Drug therapy for schizophrenia, Clozapine, Confidence intervals, Drug resistance, Longitudinal method, Odds ratio
Abstract: BackgroundClozapine remains the only evidence-based antipsychotic for treatment-resistant schizophrenia (TRS). The ability to predict which patients with their first onset of schizophrenia would subsequently meet criteria for treatment resistance (TR) could help to diminish the severe functional disability which may ensue if TR is not recognized and correctly treated.MethodThis is a 5-year longitudinal assessment of clinical outcomes in a cohort of 246 first-episode schizophrenia spectrum patients recruited as part of the NIHR Genetics and Psychosis (GAP) study conducted in South London from 2005 to 2010. We examined the relationship between baseline demographic and clinical measures and the emergence of TR. TR status was determined from a review of electronic case records. We assessed for associations with early-, and late-onset TR, and non-TR, and differences between those TR patients treated with clozapine and those who were not.ResultsSeventy per cent (n = 56) of TR patients, and 23% of the total study population (n = 246) were treatment resistant from illness onset. Those who met criteria for TR during the first 5 years of illness were more likely to have an early age of first contact for psychosis (<20 years) [odds ratio (OR) 2.49, 95% confidence interval (CI) 1.25–4.94] compared to those with non-TR. The relationship between an early age of first contact (<20 years) and TR was significant in patients of Black ethnicity (OR 3.71, 95% CI 1.44–9.56); and patients of male gender (OR 3.13 95% CI 1.35–7.23).ConclusionsFor the majority of the TR group, antipsychotic TR is present from illness onset, necessitating increased consideration for the earlier use of clozapine. [ABSTRACT FROM PUBLISHER]
Copyright of Psychological Medicine is the property of Cambridge University Press and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
FullText Text:
  Availability: 0
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 120529641
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses.
– Name: Author
  Label: Authors
  Group: Au
  Data: &lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Ajnakina%2C+O%2E%22&quot;&gt;Ajnakina, O.&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Trotta%2C+A%2E%22&quot;&gt;Trotta, A.&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Demjaha%2C+A%2E%22&quot;&gt;Demjaha, A.&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Reis+Marques%2C+T%2E%22&quot;&gt;Reis Marques, T.&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22MacCabe%2C+J%2E+H%2E%22&quot;&gt;MacCabe, J. H.&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Gaughran%2C+F%2E%22&quot;&gt;Gaughran, F.&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Murray%2C+R%2E+M%2E%22&quot;&gt;Murray, R. M.&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Lally%2C+J%2E%22&quot;&gt;Lally, J.&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Shergil%2C+S%2E+S%2E%22&quot;&gt;Shergil, S. S.&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Dazzan%2C+P%2E%22&quot;&gt;Dazzan, P.&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22David%2C+A%2E+S%2E%22&quot;&gt;David, A. S.&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Howes%2C+O%2E+D%2E%22&quot;&gt;Howes, O. D.&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Di+Forti%2C+M%2E%22&quot;&gt;Di Forti, M.&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Kolliakou%2C+A%2E%22&quot;&gt;Kolliakou, A.&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Mondelli%2C+V%2E%22&quot;&gt;Mondelli, V.&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Pariante%2C+C%2E%22&quot;&gt;Pariante, C.&lt;/searchLink&gt;
– Name: TitleSource
  Label: Source
  Group: Src
  Data: &lt;searchLink fieldCode=&quot;JN&quot; term=&quot;%22Psychological+Medicine%22&quot;&gt;Psychological Medicine&lt;/searchLink&gt;. Nov2016, Vol. 46 Issue 15, p3231-3240. 10p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: &lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Drug+therapy+for+schizophrenia%22&quot;&gt;Drug therapy for schizophrenia&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Clozapine%22&quot;&gt;Clozapine&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Confidence+intervals%22&quot;&gt;Confidence intervals&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Drug+resistance%22&quot;&gt;Drug resistance&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Longitudinal+method%22&quot;&gt;Longitudinal method&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Odds+ratio%22&quot;&gt;Odds ratio&lt;/searchLink&gt;
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: BackgroundClozapine remains the only evidence-based antipsychotic for treatment-resistant schizophrenia (TRS). The ability to predict which patients with their first onset of schizophrenia would subsequently meet criteria for treatment resistance (TR) could help to diminish the severe functional disability which may ensue if TR is not recognized and correctly treated.MethodThis is a 5-year longitudinal assessment of clinical outcomes in a cohort of 246 first-episode schizophrenia spectrum patients recruited as part of the NIHR Genetics and Psychosis (GAP) study conducted in South London from 2005 to 2010. We examined the relationship between baseline demographic and clinical measures and the emergence of TR. TR status was determined from a review of electronic case records. We assessed for associations with early-, and late-onset TR, and non-TR, and differences between those TR patients treated with clozapine and those who were not.ResultsSeventy per cent (n = 56) of TR patients, and 23% of the total study population (n = 246) were treatment resistant from illness onset. Those who met criteria for TR during the first 5 years of illness were more likely to have an early age of first contact for psychosis (&lt;20 years) [odds ratio (OR) 2.49, 95% confidence interval (CI) 1.25–4.94] compared to those with non-TR. The relationship between an early age of first contact (&lt;20 years) and TR was significant in patients of Black ethnicity (OR 3.71, 95% CI 1.44–9.56); and patients of male gender (OR 3.13 95% CI 1.35–7.23).ConclusionsFor the majority of the TR group, antipsychotic TR is present from illness onset, necessitating increased consideration for the earlier use of clozapine. [ABSTRACT FROM PUBLISHER]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: &lt;i&gt;Copyright of Psychological Medicine is the property of Cambridge University Press and its content may not be copied or emailed to multiple sites without the copyright holder&#39;s express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.&lt;/i&gt; (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=120529641
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1017/S0033291716002014
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 10
        StartPage: 3231
    Subjects:
      – SubjectFull: Drug therapy for schizophrenia
        Type: general
      – SubjectFull: Clozapine
        Type: general
      – SubjectFull: Confidence intervals
        Type: general
      – SubjectFull: Drug resistance
        Type: general
      – SubjectFull: Longitudinal method
        Type: general
      – SubjectFull: Odds ratio
        Type: general
    Titles:
      – TitleFull: Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Ajnakina, O.
      – PersonEntity:
          Name:
            NameFull: Trotta, A.
      – PersonEntity:
          Name:
            NameFull: Demjaha, A.
      – PersonEntity:
          Name:
            NameFull: Reis Marques, T.
      – PersonEntity:
          Name:
            NameFull: MacCabe, J. H.
      – PersonEntity:
          Name:
            NameFull: Gaughran, F.
      – PersonEntity:
          Name:
            NameFull: Murray, R. M.
      – PersonEntity:
          Name:
            NameFull: Lally, J.
      – PersonEntity:
          Name:
            NameFull: Shergil, S. S.
      – PersonEntity:
          Name:
            NameFull: Dazzan, P.
      – PersonEntity:
          Name:
            NameFull: David, A. S.
      – PersonEntity:
          Name:
            NameFull: Howes, O. D.
      – PersonEntity:
          Name:
            NameFull: Di Forti, M.
      – PersonEntity:
          Name:
            NameFull: Kolliakou, A.
      – PersonEntity:
          Name:
            NameFull: Mondelli, V.
      – PersonEntity:
          Name:
            NameFull: Pariante, C.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 11
              Text: Nov2016
              Type: published
              Y: 2016
          Identifiers:
            – Type: issn-print
              Value: 00332917
          Numbering:
            – Type: volume
              Value: 46
            – Type: issue
              Value: 15
          Titles:
            – TitleFull: Psychological Medicine
              Type: main
ResultId 1